Nivolumab Maintenance as Monotherapy after Carboplatin Plus Nab- Paclitaxel for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Study Protocol for Feasibility

Journal Title: UNKNOWN - Year 2017, Vol 7, Issue 5

Abstract

The aim of this study is to determine the feasibility of nivolumab as maintenance therapy after first-line chemotherapy with carboplatin plus nab-paclitaxel in non-small-cell lung cancer. Since we cannot change the dose of nivolumab, we will investigate the recommended doses and cycles of pretreatment chemotherapy with carboplatin plus nab-paclitaxel that affect maintenance therapy. The primary endpoint is incidence of any grade ≥ 3 adverse events during the first 12 weeks of nivolumab treatment. Twelve patients are required in this study

Authors and Affiliations

Masao Ichiki, Ken Masuda, Chiyo Yano, Yusuke Okayama, Hanako Oda, Yohei Imamura, Hiroaki Takeoka, Tomoaki Hoshino

Keywords

Related Articles

Preparation with Mechanical Bowel Cleansing or/and Oral Antibiotics or Nothing for Elective Colorectal Surgery: Two-Two-Arm Multicentre Randomised Controlled Studies (MECCLANT –C and –R Trials)

Background: Based on sound evidence, traditional mechanical bowel preparation for elective colorectal surgery has mostly been abandoned during the last two decades. However, more recent evidence from USA large databases...

Design of a Multicenter, Randomized, Open Label, Parallel Group Study to Evaluate the Efficacy of Loxoprofen on Acute-Phase Reactions in Japanese Primary Osteoporosis Patients Treated with Zoledronic Acid

Treatment of osteoporosis with once-yearly zoledronic acid was approved in September 2016 in Japan. Like other bisphosphonates, zoledronic acid causes acute-phase responses (APRs), which are more severe in Asian populati...

Nivolumab Maintenance as Monotherapy after Carboplatin Plus Nab- Paclitaxel for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Study Protocol for Feasibility

The aim of this study is to determine the feasibility of nivolumab as maintenance therapy after first-line chemotherapy with carboplatin plus nab-paclitaxel in non-small-cell lung cancer. Since we cannot change the dose...

Assessment of Human Natriuretic Peptides (B), Human N-Terminal Pro-BNP and Nor-epinephrine as Neurohumoral Markers in Sleep Disordered Breathing among Heart Failure Patients in Upper Egypt

Objective: The purposes of this study are to: (1) Measure neurohumoral activation in heart failure patients with and without Sleep Disordered Breathing; (2) Assessment of neurohumoral markers with the severity of sleep a...

Neurofibromatosis Type 1 and Recurrent Metastatic Low-Grade Fibromyxoid Sarcoma: Case Report about a Rare Association

Neurofibromatosis type 1 is the most frequent phacomytosis. Patients with neurofibromatosis type 1 (NF1) have a high risk to develop benign or malignant tumors of neurogenic or non-neurogenic origin. The association of (...

Download PDF file
  • EP ID EP387005
  • DOI 10.4172/2167-0870.1000325
  • Views 64
  • Downloads 0

How To Cite

Masao Ichiki, Ken Masuda, Chiyo Yano, Yusuke Okayama, Hanako Oda, Yohei Imamura, Hiroaki Takeoka, Tomoaki Hoshino (2017). Nivolumab Maintenance as Monotherapy after Carboplatin Plus Nab- Paclitaxel for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Study Protocol for Feasibility. UNKNOWN, 7(5), 1-3. https://europub.co.uk/articles/-A-387005